

Results of Share Purchase Plan Offer

HeraMED Limited (ASX:HMD) (“HeraMED” or the “Company”), a medical data and technology company leading the digital transformation of maternity care, is pleased to announce that it has received \$233,000 in applications for 2,588,879 fully paid ordinary shares at the issue price of \$0.09 under the 2020 Share Purchase Plan (“SPP”) which closed on 9 July 2020.

The SPP is part of a capital initiative to raise up to ~3.82 million, as announced on 5 June 2020, to strengthen the Company’s balance sheet and accelerate the commercial rollout of its proprietary digital pregnancy monitoring platform, HeraCARE.

Combined with the proceeds from the placement of ~2.32 million, HeraMED has raised a total of ~2.55 million from this initiative to date.

The Company together with Henslow Pty Ltd will now seek to place the shortfall of up to approximately 14,077,787 SPP Shares to professional, sophisticated and other exempt investors. Further announcements will be made regarding any shortfall placement at the applicable times. Please note as set out in the Company’s announcement dated 5 June 2020, the Company has already received firm indicative bids for placing over half the shortfall value of the SPP.

An Appendix 2A will be released to the ASX when the SPP Shares are issued on 15 July 2020. Holding statements will be dispatched to successful applicants and trading of the SPP Shares on ASX is expected to commence on 16 July 2020. Shares issued under the SPP will rank equally with HeraMED’s existing ordinary shares upon issue.

This announcement has been authorised by the Board of HeraMED Limited.

-ENDS-

HeraMED Limited
CEO and Co-Founder
David Groberman
M: +972 52 6991188
E: David@hera-med.com

Company Secretary
Jonathan Hart
T: +61 2 8379 2961
E: Jonathan@hera-med.com

Media Enquiries
Melissa Hamilton
Media & Capital Partners
M: +61 4 1775 0274
E: Melissa.hamilton@mcpartners.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data and a digital social networking dashboard.

About HeraCARE

The Company’s proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.